Tenmile is an Australian health technology venture capital firm backed by Tattarang, investing in biotech, medtech, and digital health companies. It focuses on early-stage companies from seed through commercialization, aiming to connect Australian innovation to global markets.
38% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $88.8M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$173.6M
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| LLimmaTech Biologics | Series A | $37M | Oct 2023 |
| LLimmaTech Biologics AG | Series A | $37M | Jan 2023 |
 Aravax | Series B | $42.2M | Jan 2022 |
 AdvanCell | Series D | $315M | — |
 Syndeio Biosciences | Unknown | $90M | — |
| AAntares Therapeutics | Series A | $177M | — |
 Psylo | Seed | $5M | — |
| PProton Intelligence | Seed | $7.0M | — |
Top Co-Investors
Catalio Capital Management2 shared
Abingworth LLP2 shared
Brandon Capital2 shared
Eli Lilly and Company2 shared
Palo Santo2 shared
AXA IM Alts2 shared
Sanofi Ventures1 shared
Eventide Asset Management1 shared
T. Rowe Price1 shared
Alpha Wave Global1 shared
SV Health Investors1 shared
Time BioVentures1 shared
Morningside1 shared
SymBiosis1 shared
Ally Bridge Group1 shared
Bain Capital Life Sciences1 shared
AbbVie1 shared
ARCH Venture Partners1 shared
Atlas Venture1 shared
Cormorant Asset Management1 shared
Last updated: 8 September 2026